Araris Biotech AG
Edit

Araris Biotech AG

https://ararisbiotech.com/
Last activity: 30.05.2025
Active
Categories: BioTechBuildingDrugEngineeringHealthTechMedTechPlatformTechnology
Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich focusing on the commercialization of a novel antibody-drug conjugate (ADC)-linker technology. Araris' innovative platform allows for the attachment of any payload to "off the shelf" antibodies without the need of prior antibody engineering in one-step. The resulting ADCs have a well-defined drug-to-antibody ratio, are stable and monomeric. All these favorable properties contribute to the high efficacy, stability and low level of toxicity observed so far. In summary, the straightforward drug conjugation, versatility of the technology and high in vivo efficacy enable the generation of ADC compounds for the treatment of patients with a high unmet medical need.
Mentions
43
Location: Switzerland, Zurich
Total raised: $46.11M

Investors 4

Funding Rounds 4

DateSeriesAmountInvestors
05.05.2023Grant$2.8M-
05.10.2022-$24M-
22.10.2020Seed$16.75M-
20.08.2019Seed$2.56M-

Mentions in press and media 43

DateTitleDescription
30.05.2025Schweizer Biotech-Startups dominieren europäischen Award Das Komitee des Strüngmann Awards hat diese Woche die diesjährigen Finalistinnen und Finalisten bekanntgegeben. Vergeben wird der mit 100.000 Euro dotierte Preis am 3. Juli. In das Finale geschafft haben es: Dragan Grabulovski | Philipp Sp...
28.03.2025Schroders upgrades Revolut stake in former Woodford trust by 85 per centA Schroders trust formerly run by star stockpicker Neil Woodford has upgraded the value of its stake in Revolut by 85 per cent, implying the fintech firm is worth $48bn (£37.1bn). The Schroders valuation would put Revolut, which has been mu...
17.03.2025Taiho Pharmaceutical to acquire Araris Biotech for up to USD 1.1 billion Araris is a spin-off company of the Paul-Scherrer-Institute in Switzerland and pioneering the development of best-in-class ADCs with superior design, high linker solubility and simple manufacturing that address the shortcomings of current ...
08.01.2025Araris enters multi-million contract with Chugai Araris Biotech is a leading independent company pioneering the future of antibody-drug conjugates (ADCs) and redefining the entire paradigm of targeted cancer therapy and beyond. Araris’ proprietary conjugation and multi-payload technology...
26.09.2024Araris Biotech expands its IP portfolio Founded as spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich, Araris Biotech has developed AraLinQ, a proprietary antibody-drug conjugate (ADC) technology that enables best-in-class ADCs with significantly enhanced eff...
25.09.2024An unprecedented 66 alumni from Venture Kick clinched positions in the TOP 100 Swiss Startup Awards 2024 ranking, setting a new recordVenture Kick alumni were highlighted in the thirteenth edition of the TOP 100 Swiss Startup Awards annual ranking, with alums sweeping the podium, as well as 9 of the top 10 positions. 9 Venture Kick startups ranked in the TOP 10 #1 DePoly ...
06.03.2024Araris Biotech AG to Present Data on Antibody-Drug Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024-
12.11.2023Araris Biotech AG Announces Research Collaboration with Taiho PharmaceuticalAU ZH, SWITZERLAND, November 8, 2023 – Araris Biotech AG (“Araris”), a Swiss oncology biotech company developing next-generation antibody drug conjugates (ADCs), today announced they have entered a collaboration agreement under which Araris...
08.11.2023Araris to develop drug candidates for Japanese pharma company
09.10.2023Industry veterans take on executive roles in startups
Show more

Reviews 0

Sign up to leave a review

Sign up Log In